A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Inclusion Criteria

• •Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor
• •Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)/ Microsatellite Instability (MSI) status at the time of Pre-screening and MMR/MSI status will be determined by central reference laboratory
• •Provides an archival or fresh (preferred) formalin fixed, paraffin embedded (FFPE) sample
• •Intends to receive GSK5460025 as next treatment
• •Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• •Is expected to have a minimum of 3 months life expectancy
• •Has adequate organ function, as defined in the protocol
• •Has histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor and has exhausted all standard of care treatment options
• •Has histologically diagnosed advanced (unresectable, metastatic or recurrent) Colorectal cancer (CRC) or Endometrial cancer (EC)
• •Has received at least 1 but no more than 3 lines of systemic anticancer therapy for their advanced (unresectable, metastatic or recurrent) disease including at least one line of Immune checkpoint inhibitors (ICI) therapy
• •Has measurable disease (i.e., at least 1 target lesion) during the Screening period per RECIST 1.1, as determined by the investigator